October 24, 2016 4:13 PM ET

Life Sciences Tools and Services

Company Overview of BioGenex Laboratories, Inc.

Company Overview

BioGenex Laboratories, Inc., designs, develops, manufactures, and commercializes automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The company offers a range of slide-based tissue staining products to support assay development in translational research and clinical diagnosis of cancers. It offers products in the areas of immunohistochemistry for the localization of antigen within a cell or a tissue with high resolution; in situ hybridization for precise detection and localization of a specific nucleic acid sequence within a histologic section; and fluorescent in situ hybridization that is used in clinical genetics, neuros...

49026 Milmont Drive

Fremont, CA 94538

United States

Founded in 1981





Key Executives for BioGenex Laboratories, Inc.

Co-Founder, Chairman and Chief Executive Officer
Chief Financial Officer, Senior Vice President and General Manager
Vice-President of Operations
Director of Business Development
Academic Partner and Member of Scientific Advisory Board
Age: 71
Compensation as of Fiscal Year 2016.

BioGenex Laboratories, Inc. Key Developments

BioGenex Launches Two New Antibodies for Cancer Diagnosis

BioGenex announced the release of two new antibodies for the diagnosis of cancer. The new antibodies against PMS2 (clone EP51) and CK5 (clone EP24), are rabbit polyclonal immunohistochemistry (IHC) grade antibodies and are offered together with BioGenex pre-treatment reagents, detection systems and validated protocols for crisp and intense staining. Both antibodies are available as concentrated or ready-to-use (RTU) format and are compatible with BioGenex advanced automated staining systems. PMS2 - PMS2 antibody is intended to aid in the classification of colorectal carcinoma. PMS2 protein is a mismatch repair endonuclease involved in DNA mismatch repair. Carriers of the mismatch repair gene mutations have a high lifetime risk of developing Hereditary Non-Polyposis Colon Cancer (HNPCC) and several other cancers including endometrial cancer due to MSI caused by accumulation of DNA replication errors in proliferating cells. Loss of PMS2 protein has been reported in colon carcinomas and PMS2 antibody in combination with MLH1 and MSH2 antibodies is helpful in diagnosis of microsatellite instability (MSI). CK5 – Cytokeratin 5 is a basal cell marker and used as a negative indicators of malignancy. Keratins are cytoplasmic intermediate filament proteins expressed by epithelial cells. The mitotically active basal layers of most stratified squamous epithelia express 10% to 30% of their total protein as keratin. The two keratins specifically expressed in these cells are the type II keratin CK5 and its corresponding partner, type I keratin CK14, both of which are essential for the formation of 8-nm filaments. CK5 and calretinin have been useful as markers suggestive of mesothelioma. Their expression is analyzed for the histological differential diagnosis with adenocarcinomas, especially when confronting with metastatic tumors of unknown origin. CK5 labels myoepithelial cells of breast and prostate basal cells. A cocktail of CK5, CK14 and p63, has been used as a sensitive and specific basal cell marker of basal-like phenotype of breast carcinoma and to differentiate normal and prostate cancer. Both PMS2 and CK5 antibodies are available as 0.5 or 1.0 mL concentrated forms and as 5 mL ready-to-use (RTU) solution for Manual use. A 10 mL (100 tests) RTU solution is available for BioGenex i6000 Autostainer and 16 ml (200 tests) or 5 ml (50 test) RTU solutions in RFID tagged vials, are available for Xmatrx Elite.

BioGenex Launches the Integrated eFISHiency System for the Analysis of Solid Tumors and Hematological Malignancies with Streamlined & Simplified Protocol

BioGenex is unlocking the power of DNA to revolutionize cancer research and tumor analysis with the launching its new and improved integrated eFISHiency System. This complete Laboratory Workflow Solution includes probes, Detection Systems and Smart Automation for FISH analysis. FISH is a robust technique used for the detection of chromosomal aberrations and is invaluable for both research and diagnosis of solid tumors and hematological malignancies. Until now, cytogenetic laboratories had to dedicate most of their resources to complicated, time-consuming, manual FISH staining or had to purchase expensive and large automation systems. With over 1.5 million new cancer cases per year - there is an urgent need for a small, affordable and accurate FISH automation system that can save money, and more importantly, help save lives. BioGenex eFISHiency system is the only integrated FISH workflow solution in the market offering an affordable, yet fast and accurate FISH automation. This system reduces hands-on processing time to less than 30 minutes, has the ability to run up to 10 FISH protocols simultaneously and provides validated reagents and protocols for optimal results. The eFISHiency system includes: The affordable FISH automation system that fits on a bench-top " Xmatrx Nano, 65 highly specific FISH probes, FISH Visualization kits for either FFPE or cell samples, Validated FISH protocols, FISH consumables and Performance guaranteed. BioGenex eFISH probes are processed by a unique Repeat Subtraction Technique resulting in advanced specificity and improved signal intensity. The new and improved eFISH kits contain ready-to-use (RTU) protease solutions (Liquid Pepsin) and improved pre-treatment (EZ-AR2) and post-hybridization stringency wash solutions. eFISH-Histo kit was specifically developed for fixed paraffin blocks (FFPE) while eFISH Cyto kit is for cell samples such as bone marrow aspirate, peripheral blood or cell lines. The DAPI/anti-fade reagent is a ready-to-use solution for mounting and nuclear counter-staining and was designed to minimize bleaching of fluorescence dyes during microscopic evaluation. BioGenex FISH consumables include positively-charged barrier slides, coverslips and pipette tips. The unique barrier slides and oil seal technology effectively form a sealed reaction micro-chamber that prevents evaporation of micro-reagents during high temperature steps, eliminating the need for messy rubber cement and thereby reducing set-up time. The reaction micro-chamber reduces micro-reagent consumption by up to 90% thus reducing overall cost and eliminating waste.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioGenex Laboratories, Inc., please visit biogenex.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.